Anna Gluskin: We believe that as soon as we start getting registrations all around the world, we believe that we probably will attract a major pharma that will negotiate a global agreement. That certainly is the major driver, because as soon as big pharma throws the resources that they have to bring this product to the patients, our investors should be able to capitalize on that.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.